vIGA与BSA乘积在儿童和成人特应性皮炎中的测量性能
该前瞻性皮肤科实践研究纳入653例特应性皮炎患者,评估vIGA与BSA乘积(vIGA*BSA及vIGA*cBSA)的测量性能。结果显示其与BSA、EASI、客观SCORAD有良好收敛效度,与患者报告结局弱至中等相关,具有良好的区分效度、反应度和信度,无地板/天花板效应,并建立了可解释性阈值和临床重要差异。
要点
- vIGA*BSA与EASI、客观SCORAD收敛效度良好(ρ=0.94、0.88)
- 与瘙痒NRS、POEM、DLQI等患者报告结局弱至中等相关
- 信度良好(ICC 0.72-0.74),无地板/天花板效应,并建立了阈值
核心结论
- vIGA*BSA和vIGA*cBSA在成人和儿童AD中显示良好的收敛效度、区分效度、信度、反应度和可解释性,适用于临床实践。
- vIGA*BSA和vIGA*cBSA的收敛效度略低于EASI或客观SCORAD,但收集和评分可能更高效。
研究设计与样本
- 前瞻性皮肤科实践研究,使用问卷和皮肤科医生评估,纳入653例成人和儿童AD患者。
主要发现
- vIGA*BSA与BSA的Spearman ρ=0.97,vIGA*cBSA与BSA的ρ=0.93。
- vIGA*BSA与EASI的ρ=0.94,vIGA*cBSA与EASI的ρ=0.92;与客观SCORAD的ρ分别为0.88和0.89。
- 与平均瘙痒NRS的ρ均为0.22,与最严重瘙痒NRS的ρ分别为0.27和0.28;与POEM的ρ分别为0.44和0.43;与DLQI的ρ分别为0.48和0.49;与ItchyQOL的ρ分别为0.45和0.46;与PROMIS睡眠障碍的ρ分别为0.46和0.37;与睡眠相关损害的ρ均为0.31。
- 信度ICC(95%CI)分别为0.72(0.60-0.81)和0.74(0.62-0.82),无地板或天花板效应。
- 建立了可解释性 bands 和临床重要差异的阈值。
关键数值与推荐
- vIGA*BSA与BSA的收敛效度ρ=0.97,vIGA*cBSA与BSA的ρ=0.93。
- vIGA*BSA与EASI的ρ=0.94,vIGA*cBSA与EASI的ρ=0.92;与客观SCORAD的ρ分别为0.88和0.89。
- 信度ICC(95%CI):vIGA*BSA为0.72(0.60-0.81),vIGA*cBSA为0.74(0.62-0.82)。
- 与平均瘙痒NRS的ρ均为0.22,与最严重瘙痒NRS的ρ分别为0.27和0.28。
临床怎么用
- vIGA*BSA和vIGA*cBSA可用于临床实践中评估AD严重程度,收集和评分可能更高效。
- 可参考已建立的阈值解释评分变化和临床重要差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice. OBJECTIVES: To determine the measurement properties of the product of validated Investigator's Global Assessment for AD (vIGA) and body surface area (BSA) overall or divided into six categories (cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%) and compare with other clinician-reported and patient-reported outcomes in adults and children with AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 653). RESULTS: vIGA*BSA and vIGA*cBSA had good convergent validity with BSA (Spearman's ρ = 0.97 and 0.93), eczema area and severity index (ρ = 0.94 and 0.92), and objective SCORAD (ρ = 0.88 and 0.89); and weak-to-good convergent validity with Numeric Rating Scale average itch (ρ = 0.22 and 0.22) and worst itch (ρ = 0.27 and 0.28), Patient-Oriented Eczema Measure (ρ = 0.44 and 0.43), Dermatology Life Quality Index (ρ = 0.48 and 0.49), ItchyQOL (ρ = 0.45 and 0.46), PROMIS Sleep Disturbance (ρ = 0.46 and 0.37) and sleep-related impairment (ρ = 0.31 and 0.31) in adults and/or children; very good discriminant validity for physician-reported global AD severity; good responsiveness to change of severity of AD and itch; and good reliability (intraclass correlation coefficient [95% confidence interval]: 0.72 [0.60-0.81] and 0.74 [0.62-0.82]) with no floor or ceiling effects. Thresholds for interpretability bands and clinically important difference were established. CONCLUSIONS: vIGA*BSA and vIGA*cBSA scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD, and were feasible for use in clinical practice. vIGA*BSA and vIGA*cBSA had slightly lower convergent validity than EASI or objective SCORAD, but might be more efficient to collect and score.
引用
- Silverberg JI, Lei D, Yousaf M, et al. Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. PMID: 32745300. doi:10.1111/jdv.16846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。